Treatment

RLY-4008 clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
This study is testing a new medicine, RLY-4008, for people with advanced cancers, especially a type of liver cancer called cholangiocarcinoma. It's looking to see how safe the medicine is, what dose works best, and if it can shrink tumors or stop them from growing.
For: Cholangiocarcinoma (CCA) and Other Advanced Solid Tumors
Spain · Sweden · Netherlands